加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$2.095
+US$0.055 · +2.70%
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
常规交易时段
US$2.095
+US$0.055 · +2.70%
盘中时间采用ET。市场数据可能有所延迟。
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
日内区间
当前US$2.095
52周区间
当前US$2.095
盘中时间采用ET。市场数据可能有所延迟。
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
日内区间
当前US$2.095
52周区间
当前US$2.095
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8.1万 USD | 7.7万 USD | 30.6万 USD | 26.8万 USD | 8.2万 USD |
| 销货成本 | 16.4万 USD | 8.2万 USD | 21万 USD | 19.3万 USD | 3.7万 USD |
| 毛利 | −8.3万 USD | −5000 USD | 9.6万 USD | 7.5万 USD | 4.5万 USD |
| 研究与开发 | 1317.1万 USD | 1473万 USD | 1522.5万 USD | 1424.4万 USD | 1101.9万 USD |
| 销售、一般及管理费用 | 2325万 USD | 2190万 USD | 2469.2万 USD | 3148.3万 USD | 2442.1万 USD |
| 营业费用 | 3642.1万 USD | 3663万 USD | 3991.7万 USD | 4572.7万 USD | 3544万 USD |
| 利息收入 | 458.5万 USD | 274.7万 USD | 164万 USD | 45.6万 USD | 14.5万 USD |
| 利息支出 | 9000 USD | 2.8万 USD | 5.5万 USD | 6.1万 USD | 74.6万 USD |
| 折旧和摊销 | 94万 USD | 83.3万 USD | 90万 USD | 75.6万 USD | 65.9万 USD |
| 营业利润 | −3650.4万 USD | −3663.5万 USD | −3982.1万 USD | −4565.2万 USD | −3539.5万 USD |
| 净利润 | −3192.8万 USD | −3289.8万 USD | −3624.2万 USD | −4418.6万 USD | −3500.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 186.40%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI188.05万0.00%2.3万亿 USD0.03%US$381.79-0.04%
Vanguard Extended Market ETFVXF80.6万0.00%954亿 USD0.05%US$234.19-0.35%
iShares Micro-Cap ETFIWC21.14万0.02%13.17亿 USD0.60%US$182.24-0.42%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM10万0.09%1.17亿 USD0.73%US$15.86-0.50%
Avantis U.S. Small Cap Equity ETFAVSC1.1万—30.82亿 USD0.25%US$70.11+0.19%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.03万0.00%455.91亿 USD0.17%US$84.45+0.01%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
